Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Concerns rise over proposal by CMS to level E/M payments
CMS proposed rule, CMS-1693-P
Key clinical point: Some specialties would be paid less under proposed payment changes for 2019.
Major finding: New patient visits (levels 2-5) would be paid at $135 and established patient visits (levels 2-5) would be paid at $93.
Study details: The physician fee schedule proposal would pay level 2-5 E/M visits at the same rate, and reduce some documentation requirements.
Disclosures: No relevant financial disclosures were reported.
CMS proposed rule, CMS-1693-P
This Week's Must Reads
Case studies shed light on treatment for rare form of MCL , Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.
Histopathological clues for differentiating follicular lymphomas, Servitje O et al. J Cutan Pathol. 2019;46:182-9.
Single agent daratumumab is not an option in B-cell lymphomas, Salles G et al. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. doi: 10.1016/j.clml.2018.12.013.
Ibrutinib combo advances in CNS lymphoma, Grommes C et al. Blood. 2019;133(5):436-45.
Best frontline options for advanced follicular lymphoma, Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.
Must Reads in Business of Medicine
For lymphoma patients, insurance is a matter of life or death , Goldstein JS et al. Blood. 2018 Jul 24. doi: 10.1182/blood-2018-03-839035
Concerns rise over proposal by CMS to level E/M payments , CMS proposed rule, CMS-1693-P
Expansion in clinical trial eligibility requested by ASCO, Friends of Cancer and ASCO letter to the FDA
CMS wants to flatten E/M payments, CMS proposed rule, CMS-1693-P
Lay health workers can assist with end-of-life care, Patel MI et al. JAMA Oncology. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2446.